DE602004010178D1 - Benzothiazol-derivate zur behandlung von diabetes - Google Patents

Benzothiazol-derivate zur behandlung von diabetes

Info

Publication number
DE602004010178D1
DE602004010178D1 DE602004010178T DE602004010178T DE602004010178D1 DE 602004010178 D1 DE602004010178 D1 DE 602004010178D1 DE 602004010178 T DE602004010178 T DE 602004010178T DE 602004010178 T DE602004010178 T DE 602004010178T DE 602004010178 D1 DE602004010178 D1 DE 602004010178D1
Authority
DE
Germany
Prior art keywords
unsubstituted
substituted
treatment
group
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004010178T
Other languages
English (en)
Other versions
DE602004010178T2 (de
Inventor
Pascale Gaillard
Jean-Pierre Gotteland
Pierre-Alain Vitte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA filed Critical Laboratoires Serono SA
Publication of DE602004010178D1 publication Critical patent/DE602004010178D1/de
Application granted granted Critical
Publication of DE602004010178T2 publication Critical patent/DE602004010178T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE602004010178T 2003-09-12 2004-09-08 Benzothiazol-derivate zur behandlung von diabetes Active DE602004010178T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12
EP03102740 2003-09-12
PCT/EP2004/052090 WO2005025567A1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Publications (2)

Publication Number Publication Date
DE602004010178D1 true DE602004010178D1 (de) 2007-12-27
DE602004010178T2 DE602004010178T2 (de) 2008-09-11

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004010178T Active DE602004010178T2 (de) 2003-09-12 2004-09-08 Benzothiazol-derivate zur behandlung von diabetes

Country Status (18)

Country Link
US (2) US20070088017A1 (de)
EP (1) EP1696909B1 (de)
JP (1) JP5021307B2 (de)
AT (1) ATE378047T1 (de)
AU (1) AU2004271740B2 (de)
CA (1) CA2534314C (de)
CY (1) CY1107820T1 (de)
DE (1) DE602004010178T2 (de)
DK (1) DK1696909T3 (de)
ES (1) ES2297494T3 (de)
HK (1) HK1096594A1 (de)
HR (1) HRP20070527T3 (de)
IL (1) IL174250A (de)
NO (1) NO20061600L (de)
PL (1) PL1696909T3 (de)
PT (1) PT1696909E (de)
SI (1) SI1696909T1 (de)
WO (1) WO2005025567A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
KR101202240B1 (ko) 2006-08-24 2012-11-16 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
RU2717835C2 (ru) 2012-07-13 2020-03-26 Джи Ти Икс, ИНК. Способ лечения андроген-рецептор(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов (sarm)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (de) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazolderivate und ihre Verwendung als JNK Modulatoren
DK1450792T3 (da) * 2001-12-07 2007-01-29 Applied Research Systems Benzazolderivater til behandling af sclerodermia
ATE383356T1 (de) * 2002-04-25 2008-01-15 Serono Lab Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns- systems

Also Published As

Publication number Publication date
PT1696909E (pt) 2007-12-21
WO2005025567A1 (en) 2005-03-24
HRP20070527T3 (en) 2007-12-31
ATE378047T1 (de) 2007-11-15
DE602004010178T2 (de) 2008-09-11
IL174250A (en) 2011-01-31
JP2007505083A (ja) 2007-03-08
HK1096594A1 (en) 2007-06-08
EP1696909B1 (de) 2007-11-14
DK1696909T3 (da) 2008-01-02
CA2534314C (en) 2012-11-13
IL174250A0 (en) 2006-08-01
JP5021307B2 (ja) 2012-09-05
AU2004271740A1 (en) 2005-03-24
NO20061600L (no) 2006-04-07
CA2534314A1 (en) 2005-03-24
AU2004271740B2 (en) 2010-10-28
US20070088017A1 (en) 2007-04-19
US20140107116A1 (en) 2014-04-17
CY1107820T1 (el) 2013-06-19
PL1696909T3 (pl) 2008-04-30
EP1696909A1 (de) 2006-09-06
ES2297494T3 (es) 2008-05-01
SI1696909T1 (sl) 2008-02-29

Similar Documents

Publication Publication Date Title
NO20061600L (no) Bensotiazol-derivater for behandling av diabetes
NO20061614L (no) Benzimidazolacetonitriler
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
BRPI0406761A (pt) Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
ATE427926T1 (de) Cycloalkylaminderivate
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
DE60325740D1 (de) Verwendung von protein-kinase-n-beta
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
MA28339A1 (fr) Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments
SE0102299D0 (sv) Compounds
DE502006007587D1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
ATE435235T1 (de) Formulierungen glp-1-analoger fusionsproteine
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
CY1113736T1 (el) Ετεροαρυλ-ουριες και η χρηση τους ως ενεργοποιητες γλυκοκινασης
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
NO20061599L (no) Benzoksazol acetonitriler
ATE455772T1 (de) Alkinylarylcarbonsäureamide
BRPI0407758A (pt) derivados de 3-(2-fenil-oxazol-4-ilmetóxi)-ciclohexilmetóxi-acético e compostos afins como modula-dores de ppar para o tratamento de diabetes do tipo 2 e aterosclerose.
TW200740786A (en) Novel cercosporamide derivatives
BRPI0607558A2 (pt) derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt)
DE602005024539D1 (de) Neue verbindungen, ihre herstellung und verwendung
DK1656139T3 (da) Aryldicarboxamider

Legal Events

Date Code Title Description
8364 No opposition during term of opposition